Literature DB >> 24746199

The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.

Ana Mozos1, Lluis Catasús1, Emanuela D'Angelo1, Elena Serrano2, Iñigo Espinosa1, Irene Ferrer1, Cristina Pons1, Jaime Prat3.   

Abstract

Micro-RNA (miRNA) signatures influence the prognosis of cancer, but little is known about their role in myometrial invasion in endometrioid endometrial adenocarcinoma (EEC). We studied miRNA expression signatures in noninvasive and invasive EEC focusing on the alteration of miR-27 and its main target, FOXO1 as well as their relationship with the clinicopathological parameters and other genetic alterations such as PIK3CA mutations. In 25 tumors and 5 normal endometria, unsupervised hierarchical clustering analysis showed that normal endometria and noninvasive EEC were grouped together and separately from invasive and advanced stage tumors. Of the 20 miRNAs differentially expressed in noninvasive (stage IA) and myoinvasive adenocarcinomas (stage IB and IC), miR27 was overexpressed in invasive adenocarcinomas, and its expression increased linearly according to stage. Results were validated by quantitative real-time reverse transcription polymerase chain reaction in an independent series of 44 EEC. By in situ hybridization, miR-27 expression was limited to the stroma. Using quantitative real-time reverse transcription polymerase chain reaction, the expression of proapoptotic transcription factor FOXO1 was down-regulated in invasive compared with noninvasive tumors. Furthermore, we found that the expression of active caspase 3 was higher in noninvasive than invasive EEC. When stratified by PIK3CA mutations, all invasive tumors down-regulated FOXO1, but only nonmutated adenocarcinomas showed miR-27 overexpression. In conclusion, we propose that the miR27-FOXO1 tandem inhibits apoptosis and represents an alternative pathway for tumor cell survival in PIK3CA-nonmutated EEC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrioid endometrial cancer; FOXO1; PIK3CA; miR27; miRNA

Mesh:

Substances:

Year:  2014        PMID: 24746199     DOI: 10.1016/j.humpath.2013.12.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Up-regulation of miR-27 extenuates lipopolysaccharide-induced injury in H9c2 cells via modulating ICAM1 expression.

Authors:  Jing-Fang Xiang; Jian-Chun Yu; Jian-You Zhu
Journal:  Genes Genomics       Date:  2019-10-01       Impact factor: 1.839

2.  Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.

Authors:  Ayesha Joshi; Christopher Miller; Suzanne J Baker; Lora H Ellenson
Journal:  Am J Pathol       Date:  2015-02-16       Impact factor: 4.307

3.  HOXA-AS2 promotes type I endometrial carcinoma via miRNA-302c-3p-mediated regulation of ZFX.

Authors:  Ning Song; Ying Zhang; Fanfei Kong; Hui Yang; Xiaoxin Ma
Journal:  Cancer Cell Int       Date:  2020-07-31       Impact factor: 5.722

4.  MicroRNA-27 Inhibits Autophagy and Promotes Proliferation of Multiple Myeloma Cells by Targeting the NEDD4/Notch1 Axis.

Authors:  Feifei Che; Jiao Chen; Chunqian Wan; Xiaobing Huang
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

5.  TNF-α induces up-regulation of MicroRNA-27a via the P38 signalling pathway, which inhibits intervertebral disc degeneration by targeting FSTL1.

Authors:  Jie Shi; Shaoyi Wang; Qiting He; Kaiwen Liu; Wei Zhao; Qing Xie; Lei Cheng
Journal:  J Cell Mol Med       Date:  2021-06-30       Impact factor: 5.310

6.  Circulating miRNA 27a and miRNA150-5p; a noninvasive approach to endometrial carcinoma.

Authors:  Rasha Abdelmawla Ghazala; Eman Ahmed El-Attar; Ziad Sami Abouzeid
Journal:  Mol Biol Rep       Date:  2021-06-02       Impact factor: 2.316

Review 7.  MicroRNAS in endometrial cancer: recent advances and potential clinical applications.

Authors:  Megumi Yanokura; Kouji Banno; Miho Iida; Haruko Irie; Kiyoko Umene; Kenta Masuda; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  EXCLI J       Date:  2015-02-02       Impact factor: 4.068

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.